Rocket Pharmaceuticals Inc
RCKT3.364USD
-0.166-4.71%
Market hours （ET）Quotes delayed by 15 min
363.98MMarket Cap
LossP/E TTM
More Details of Rocket Pharmaceuticals Inc Company
Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company focused on the development of gene therapies for rare and devastating diseases. The Company has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.
Rocket Pharmaceuticals Inc Info
Ticker SymbolRCKT
Company nameRocket Pharmaceuticals Inc
IPO dateFeb 18, 2015
CEOShah (Gaurav D)
Number of employees299
Security typeOrdinary Share
Fiscal year-endFeb 18
Address9 Cedarbrook Drive
CityCRANBURY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code08512
Phone16464409100
Websitehttps://www.rocketpharma.com/
Ticker SymbolRCKT
IPO dateFeb 18, 2015
CEOShah (Gaurav D)
Company Executives of Rocket Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Gaurav D. Shah, M.D.
Dr. Gaurav D. Shah, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.20M
-0.52%
Dr. Kinnari Patel, Pharm.D.
Dr. Kinnari Patel, Pharm.D.
President, Head of Research and Development
President, Head of Research and Development
513.63K
-0.42%
Mr. Christopher Stevens
Mr. Christopher Stevens
Chief Operating Officer
Chief Operating Officer
407.17K
--
Mr. David P. Southwell
Mr. David P. Southwell
Independent Director
Independent Director
125.12K
+31.54%
Mr. John Militello, CPA
Mr. John Militello, CPA
Principal Accounting Officer, Vice President - Finance, Treasurer
Principal Accounting Officer, Vice President - Finance, Treasurer
59.73K
-1.79%
Dr. Mikael G. Dolsten, M.D., Ph.D.
Dr. Mikael G. Dolsten, M.D., Ph.D.
Independent Director
Independent Director
44.22K
+210.97%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Independent Director
Independent Director
40.00K
+33.33%
Dr. Fady Ibraham Malik, M.D., Ph.D.
Dr. Fady Ibraham Malik, M.D., Ph.D.
Independent Director
Independent Director
30.00K
--
Mr. Carsten Boess
Mr. Carsten Boess
Independent Director
Independent Director
30.00K
--
Mr. Piratip Pratumsuwan
Mr. Piratip Pratumsuwan
Independent Director
Independent Director
30.00K
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Gaurav D. Shah, M.D.
Dr. Gaurav D. Shah, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.20M
-0.52%
Dr. Kinnari Patel, Pharm.D.
Dr. Kinnari Patel, Pharm.D.
President, Head of Research and Development
President, Head of Research and Development
513.63K
-0.42%
Mr. Christopher Stevens
Mr. Christopher Stevens
Chief Operating Officer
Chief Operating Officer
407.17K
--
Mr. David P. Southwell
Mr. David P. Southwell
Independent Director
Independent Director
125.12K
+31.54%
Mr. John Militello, CPA
Mr. John Militello, CPA
Principal Accounting Officer, Vice President - Finance, Treasurer
Principal Accounting Officer, Vice President - Finance, Treasurer
59.73K
-1.79%
Dr. Mikael G. Dolsten, M.D., Ph.D.
Dr. Mikael G. Dolsten, M.D., Ph.D.
Independent Director
Independent Director
44.22K
+210.97%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RTW Investments L.P.
16.34%
Maverick Capital, Ltd.
7.83%
The Vanguard Group, Inc.
6.37%
BlackRock Institutional Trust Company, N.A.
5.56%
MPM BioImpact LLC
3.61%
Other
60.29%
Shareholders
Shareholders
Proportion
RTW Investments L.P.
16.34%
Maverick Capital, Ltd.
7.83%
The Vanguard Group, Inc.
6.37%
BlackRock Institutional Trust Company, N.A.
5.56%
MPM BioImpact LLC
3.61%
Other
60.29%
Shareholder Types
Shareholders
Proportion
Hedge Fund
30.19%
Investment Advisor/Hedge Fund
29.47%
Investment Advisor
23.82%
Research Firm
6.41%
Individual Investor
3.87%
Venture Capital
0.15%
Bank and Trust
0.10%
Family Office
0.08%
Insurance Company
0.03%
Other
5.88%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
494
97.15M
89.78%
-13.57M
2025Q2
493
101.52M
94.23%
-15.02M
2025Q1
494
114.28M
106.44%
-9.69M
2024Q4
469
115.66M
108.78%
+9.90M
2024Q3
442
99.39M
108.64%
-6.54M
2024Q2
434
97.04M
106.63%
-8.16M
2024Q1
431
98.54M
108.92%
-3.20M
2023Q4
427
94.76M
105.15%
-7.91M
2023Q3
413
94.89M
105.90%
+6.62M
2023Q2
408
81.61M
101.38%
-10.66M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RTW Investments L.P.
17.69M
16.39%
--
--
Sep 19, 2025
Maverick Capital, Ltd.
8.36M
7.75%
+2.82M
+50.78%
Jun 30, 2025
The Vanguard Group, Inc.
6.10M
5.65%
-502.58K
-7.61%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
6.35M
5.89%
+202.53K
+3.29%
Jun 30, 2025
MPM BioImpact LLC
3.90M
3.62%
+2.28M
+141.19%
Jun 30, 2025
Suvretta Capital Management, LLC
4.14M
3.84%
+641.33K
+18.31%
Jun 30, 2025
Millennium Management LLC
2.35M
2.18%
+1.60M
+214.37%
Jun 30, 2025
Two Sigma Investments, LP
3.23M
2.99%
+3.23M
--
Jun 30, 2025
Morgan Stanley & Co. LLC
2.02M
1.87%
+241.77K
+13.57%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.83%
Global X Genomics & Biotechnology ETF
0.42%
WisdomTree BioRevolution Fund
0.38%
Fidelity Enhanced Small Cap ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
iShares Biotechnology ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.02%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.83%
Global X Genomics & Biotechnology ETF
Proportion0.42%
WisdomTree BioRevolution Fund
Proportion0.38%
Fidelity Enhanced Small Cap ETF
Proportion0.05%
Invesco Nasdaq Biotechnology ETF
Proportion0.04%
ProShares Ultra Nasdaq Biotechnology
Proportion0.04%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.03%
iShares Biotechnology ETF
Proportion0.03%
iShares Russell 2000 Value ETF
Proportion0.02%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Rocket Pharmaceuticals Inc?
The top five shareholders of Rocket Pharmaceuticals Inc are:
RTW Investments L.P. holds 17.69M shares, accounting for 16.39% of the total shares.
Maverick Capital, Ltd. holds 8.36M shares, accounting for 7.75% of the total shares.
The Vanguard Group, Inc. holds 6.10M shares, accounting for 5.65% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.35M shares, accounting for 5.89% of the total shares.
MPM BioImpact LLC holds 3.90M shares, accounting for 3.62% of the total shares.
RTW Investments L.P. holds 17.69M shares, accounting for 16.39% of the total shares.
Maverick Capital, Ltd. holds 8.36M shares, accounting for 7.75% of the total shares.
The Vanguard Group, Inc. holds 6.10M shares, accounting for 5.65% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.35M shares, accounting for 5.89% of the total shares.
MPM BioImpact LLC holds 3.90M shares, accounting for 3.62% of the total shares.
What are the top three shareholder types of Rocket Pharmaceuticals Inc?
The top three shareholder types of Rocket Pharmaceuticals Inc are:
RTW Investments L.P.
Maverick Capital, Ltd.
The Vanguard Group, Inc.
RTW Investments L.P.
Maverick Capital, Ltd.
The Vanguard Group, Inc.
How many institutions hold shares of Rocket Pharmaceuticals Inc (RCKT)?
As of 2025Q3, 494 institutions hold shares of Rocket Pharmaceuticals Inc, with a combined market value of approximately 97.15M, accounting for 89.78% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -4.44%.
What is the biggest source of revenue for Rocket Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for Rocket Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
